目前双膦酸盐类药物治疗骨转移的主要目的是减少骨相关事件、减轻疼痛和提高生活质量。
The current aims of bi- sphosphonates for metastatic bone disease are to prevent skeletal-related events, reduce bone pain, and improve quality of life.
这一时间点后，继续双膦酸盐治疗与骨轴向力和结构完整性降低相关。
After that point, continued treatment was associated with decreased axial strength and structural integrity.
矿化程度的测定表明，低剂量和高剂量双膦酸盐组骨单位内的平均矿化程度（MDMB）都明显高于对照组，分别增加了22%和30%。
The mean degree of mineralization in bone(MDMB) in YML and YMH were significantly higher than that of CNT, and increased by 22% and 30%, respectively.
应用推荐